Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00277-022-04803-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From R-CHOP to Revolution: How CAR T-Cells, ADCs, and Bispecific Antibodies Are Transforming DLBCL Treatment.
Crit Rev Oncol Hematol
September 2025
Department of Hematology-Oncology, Hotel-Dieu de France, Beirut, Lebanon. Electronic address:
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common and aggressive subtype of non-Hodgkin lymphoma, with R-CHOP as the standard first-line treatment. However, many patients experience relapse or refractory disease, prompting the need for new therapeutic approaches. Recent advances, including chimeric antigen receptor (CAR) T-cell therapies, antibody-drug conjugates (ADCs), bispecific antibodies (bsAbs), immunomodulators, and Exportin-1 (XPO-1) inhibitors have transformed treatment strategies.
View Article and Find Full Text PDFSuccessful Treatment of Diffuse Large B-Cell Lymphoma and Antisynthetase Syndrome with Bispecific Antibody Glofitamab.
Cancer Manag Res
August 2025
Department of Hematology, Beijing Longfu Hospital, Beijing, People's Republic of China.
Glofitamab, a CD20×CD3 T-cell-engaging bispecific monoclonal antibody, has emerged as a promising therapeutic agent for relapsed/refractory B-cell non-Hodgkin lymphoma. The advent of chimeric antigen receptor T-cell therapy and T-cell-engaging bispecific antibodies has also stimulated growing interest in their potential application in autoimmune diseases. Here, we report a case of diffuse large B-cell lymphoma (DLBCL) in a patient with a long-standing history of antisynthetase syndrome (ASyS).
View Article and Find Full Text PDF[Polatuzumab vedotin in the treatment of relapsed or refractory DLBCL: a case report].
Recenti Prog Med
September 2025
Uoc Medicina, Azienda Ulss 6 Euganea, Camposampiero (Padova).
Diffuse large B-cell lymphomas (DLBCLs) represent one of the most common and aggressive forms of non-Hodgkin lymphoma (NHL), characterized by rapid B-cell growth and a significantly high risk of relapse or refractoriness. The clinical course for these patients is long and complicated with a sometimes dismal prognosis, and the therapeutic approach must include effective and innovative chemotherapeutic treatments. The therapeutic strategies for DLBCLs in recent years has seen considerable pharmacological enrichment, including drug-conjugated antibodies such as polatuzumab vedotin.
View Article and Find Full Text PDFEffectiveness and Safety of Polatuzumab Vedotin Plus an Anti-CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Cancer Med
August 2025
Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Background: Approximately 30% of patients with diffuse large B-cell lymphoma (DLBCL) relapse or are refractory to first-line treatment. This study aimed to determine the effectiveness and tolerability of the combination of Polatuzumab vedotin and Zanubrutinib plus Rituximab (Pola-ZR) or Obinutuzumab (Pola-ZG) in patients with relapsed/refractory (R/R) DLBCL.
Methods: We conducted a prospective observational study as part of our registered cohort study (NCT06203652).
Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma.
Cancers (Basel)
July 2025
Department of Malignant Hematology, Tampa General Hospital Cancer Institute, Tampa, FL 33629, USA.
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL) [...
View Article and Find Full Text PDF